Menu

Recent Interviews

Justin Reid, President and CEO, Troilus Gold Corp.

Justin Reid
President and CEO | Troilus Gold Corp.
36 Lombard Street, Floor 4, M5C 2X3 Toronto, Ontario (CAN)

info@troilusgold.com

+1 (647) 276-0050

Interview Troilus Gold: "We are convinced that Troilus is more than just a mine".


John Jeffrey, CEO, Saturn Oil + Gas Inc.

John Jeffrey
CEO | Saturn Oil + Gas Inc.
Suite 1000 - 207 9 Ave SW, T2P 1K3 Calgary (CAN)

info@saturnoil.com

+1-587-392-7900

Saturn Oil + Gas CEO John Jeffrey: "Acquisition has increased production by 2,000%"


Gary Cope, President and CEO, Barsele Minerals

Gary Cope
President and CEO | Barsele Minerals
Suite 1130 - 1055 W. Hastings Street, V6E 2E9 Vancouver (CAN)

info@barseleminerals.com

+1(604) 687-8566

Interview Barsele Minerals: 'I have never seen a project with such good general conditions'.


Interview with Cardiol Therapeutics

Interview with Cardiol Therapeutics: How the heart disease specialist company plans to take off on the Nasdaq in 2021

  • Biotech
  • Heart Disease
  • CBD
Photo credits: Cardiol Therapeutics

Cardiol Therapeutics is a biotechnology company that has declared war on potentially lethal inflammatory processes in the heart. To do this, the Company relies on the extensively researched active ingredient cannabidiol (CBD) which has been shown to reduce inflammation in a number of pre-clinical tests that have formed the basis for the Company’s Phase II/III clinical programs. The Company obtains the active ingredient synthetically and is currently researching various areas of application and forms of administration for its proprietary CBD formulation CardiolRx™. With the Company’s commercial CBD oral formulation, Cortalex™, Cardiol is already on the market with the purest CBD oil in the world and expects this product to generate major growth. Cardiol Therapeutics is now preparing to list on the Nasdaq which will position the Company to compete with the very big players in the biotech industry. In this interview, President and CEO David Elsley talks about CBD as an active ingredient, the research approach of Cardiol Therapeutics, the opportunities of the proposed Nasdaq listing for shareholders, and completely new ideas around innovative medicines. Leede Jones Gable analyst Douglas W. Loe yesterday rated the stock a 'Speculative Buy' with a price target of CAD 12.50 in an initial coverage report.

Time to read: 5 minutes | The interview was conducted by Nico Popp on 26. March 2021 in Oakville (CAN).

David Elsley, CEO, Cardiol Therapeutics

David Elsley
CEO | Cardiol Therapeutics
602-2265 Upper Middle Road East, L6H 0G5 Oakville (CAN)

info@cardiolrx.com

+1 (289) 910-0850

Topics:


Scientific foundation

news|financial: "You are a biotech company using the active ingredient cannabidiol (CBD) to treat heart disease. What about the scientific foundation for this approach?"

David Elsley, CEO, Cardiol Therapeutics
"[...] Since inflammation is a cause of heart failure, and heart failure in turn is one of the leading causes of death in the Western world [...]" David Elsley, CEO, Cardiol Therapeutics

That foundation is very broad. The active ingredient cannabidiol has been extensively researched in hundreds of studies, and there is significant evidence in the published scientific literature demonstrating the anti-inflammatory properties and effects of CBD. Our interest in developing cannabidiol as a cardioprotective drug stems from an article in the Journal of the American College of Cardiology (JACC) that examined the effects of CBD on heart disease. This scientific journal has an excellent reputation worldwide and is read widely by the cardiology community. The article on which Cardiol Therapeutics' work is based showed that CBD can prevent and potentially reverse cardiac fibrosis, a potentially fatal disease process that is caused by chronic inflammation in heart tissue. Since inflammation is a cause of heart failure, and heart failure in turn is one of the leading causes of death in the Western world, we have used these findings as an opportunity to further research and develop medicines around CBD.


Other applications of CBD

news|financial: "CBD is effective for more than just fibrosis, however...."

There are numerous pre-clinical and clinical studies being conducted with CBD around the world. There is also a growing body of scientific evidence supporting the cardioprotective role of CBD in the cardiovascular system. For these reasons, we firmly believe that CBD has the potential to revolutionize the treatment of inflammatory diseases of the heart. CBD is already being used successfully in the U.S. as an approved medication for epilepsy and we believe that the benefits of CBD in the context of heart disease may exceed this benefit.


Advantages over other agents

news|financial: "For new drugs to gain acceptance, they must offer advantages over existing agents. Where do you think those advantages might lie with your product?"

David Elsley, CEO, Cardiol Therapeutics
"[...] One of the key differentiating features of CBD is its extraordinary safety profile. [...]" David Elsley, CEO, Cardiol Therapeutics

One of the key differentiating features of CBD is its extraordinary safety profile. Other anti-inflammatory agents, such as steroids, have been studied in inflammatory heart disease, but their use has been limited as a result of toxicology concerns and risk of serious adverse side effects. CBD, on the other hand, has an excellent safety profile which has now been demonstrated in thousands pediatric patients in the U.S. and internationally. For drugs to be approved for children, they must be very safe. We believe the substantial body of evidence supporting the safety of CBD provides another major reason for advancing its development as a potentially breakthrough therapy for the treatment of cardiovascular disease.


Different dosage forms of CardiolRx™

news|financial: "Thanks to a special formula, you want to ensure that your CardiolRx™ drug remains effective despite being taken orally. How do you manage this and what is special about your approach?"

David Elsley, CEO, Cardiol Therapeutics
"[...] You can compare our approach to manufacturing CardiolRx™ to the approach Bayer has utilized for decades to mass manufacture Aspirin. [...]" David Elsley, CEO, Cardiol Therapeutics

We are pursuing two approaches for delivering therapeutic doses of CBD to patients. One is oral administration and the other is subcutaneous injection, which is similar to administering insulin. With oral administration, we benefit from the fact that we manufacture our CBD as part of a pharmaceutical process and can therefore offer high purity, very high concentration, and consistent quality. You can compare our approach to manufacturing CardiolRx™ to the approach Bayer has utilized for decades to mass manufacture Aspirin. Like Aspirin, which was first discovered and extracted from a botanical source and later produced in a laboratory, Cardiol’s approach to producing its pure CBD medicines also follows a pharmaceutical production process to ensure drug purity, consistency, stability, and affordability. The huge success of Aspirin shows just one of many examples where pharmaceutical production processes allow new important medicines to be mass produced.


An injection against heart disease?

news|financial: "And what is the CardiolRx™ injectable formulation all about?"

David Elsley, CEO, Cardiol Therapeutics
"[...] We believe this represents a potential breakthrough that could lead to a completely new way to treat heart failure [...]" David Elsley, CEO, Cardiol Therapeutics

We will be talking more about this innovation in the coming months. But this much is already clear: through subcutaneous injection, the active ingredient reaches the bloodstream far more effectively which allows more drug to reach the site of disease by avoiding the digestive system and metabolism by the liver. In this way, the CBD active ingredient in CardiolRx™ targets sites of inflammation more efficiently. We have already had initial data utilizing our injectable formulation accepted for presentation at the 2020 sessions of the American College of Cardiology that took place virtually. The findings from this pre-clinical study showed that our injectable formulation had a significant impact on inflammation and fibrosis utilizing only one tenth of the typical CBD dose required to achieve a therapeutic effect. We believe this represents a potential breakthrough that could lead to a completely new way to treat heart failure, which remains a leading cause of death and disability in the developed world.


CardiolRx™ and COVID-19

news|financial: "COVID-19 has given us all a completely unprecedented situation. Why are you driving research around your compound particularly in COVID-19 disease?"

David Elsley, CEO, Cardiol Therapeutics
"[...] The pandemic opens up the opportunity for us to conduct our studies in an accelerated manner, as there is great interest on the part of clinics and regulatory authorities to obtain effective drugs. [...]" David Elsley, CEO, Cardiol Therapeutics

We are not manufacturing a drug for COVID-19. It is also far from our intention to push ourselves into the foreground in this way. However, people with cardiovascular disease are at-risk patients who are much more vulnerable to the damaging effects of COVID-19. Even when the pandemic is over, the virus will remain and be with us, much like the annual wave of influenza. Patients who develop severe courses, often associated with inflammation, will need to be treated. The pandemic opens up the opportunity for us to conduct our studies in an accelerated manner, as there is great interest on the part of clinics and regulatory authorities to obtain effective drugs. For this reason, we are pushing ahead with studies around COVID-19, which, by the way, are well advanced. That said, our drug is intended to address heart disease in general.


Why CBD oil needs to be pure

news|financial: "You also offer Cortalex™, a CBD oil. What does your product do better than the multitude of CBD oils available today?"

David Elsley, CEO, Cardiol Therapeutics
"[...] The Canadian market for medical cannabinoids is approximately CAD 600 million, making it one of the largest markets in the world. [...]" David Elsley, CEO, Cardiol Therapeutics

Cortalex™ is a very important product for us. The Canadian market for medical cannabinoids is approximately CAD 600 million, making it one of the largest markets in the world. Cortalex™ is characterized by its extraordinary purity. Those who use the product receive a pure, consistent CBD product that is free of THC (<10ppm). THC is the active ingredient in the cannabis plant that induces intoxication, promotes memory lapses, or causes a slowed response. These effects are usually undesirable in a medical product, especially for children and elderly patients. This is why we expect many doctors to recommend Cortalex™. For example, we have seen substantial interest from pediatricians in recommending CBD as a treatment for children and adolescents with epilepsy and other central nervous system disorders. This is a patient population where it is extremely important that the CBD formulation be pure and THC free, as THC can have negative effects on brain development. From our perspective, Cortalex™ is the purest CBD in the world, and its purity even exceeds the standard set by the CBD medicine approved by the U.S. Food and Drug Administration.


Sales

news|financial: "What sales are you targeting with Cortalex™?"

We launched Cortalex™ in Canada in late 2020 and plan to ramp up marketing later this year. We believe the product can generate meaningful sales over the next twelve to eighteen months. Due to its high quality and the great importance of product purity for younger patients, we are convinced that we can gain a significant share of this market.


Cardiol Therapeutics and the Nasdaq

news|financial: "Cardiol Therapeutics has recently applied for listing on the Nasdaq. Compared to other biotech companies, you have a much lower valuation. Do you already feel strong interest from investors due to the new awareness?"

David Elsley, CEO, Cardiol Therapeutics
"[...] Given Cardiol’s current market valuation of approximately USD 130 million and the fact that we are entering a Phase II/III program, I believe the GW Pharma and MyoKardia examples underscore the potential for a significant revaluation of Cardiol to occur after a successful uplisting on the Nasdaq. [...]" David Elsley, CEO, Cardiol Therapeutics

Many of the most prominent biotechnology and life sciences companies are listed on the Nasdaq in the United States. The U.S. also represents the largest healthcare market in the world. To create broader awareness of the potential for the heart medicines we are developing, we are now pursuing an application for uplisting on the Nasdaq. We believe the potential impact such a listing can have on our current valuation is illustrated by the example of GW Pharma. This British company was initially traded on the London Stock Exchange for many years prior to uplisting on the Nasdaq. Within a very short time following its Nasdaq listing, GW Pharma’s market capitalization jumped from approximately USD 100 million to over USD 1 billion and it was recently acquired for more than USD 7 billion by Jazz Pharmaceuticals. Another interesting example is a company called MyoKardia which was valued at approximately USD 200 million when incidentally, it was at a similar stage of development as Cardiol Therapeutics is today. Following the release of MyoKardia’s Phase II trial results in a rare heart condition, its valuation rose to over USD $2 billion. Given Cardiol’s current market valuation of approximately USD 130 million and the fact that we are entering a Phase II/III program, I believe the GW Pharma and MyoKardia examples underscore the potential for a significant revaluation of Cardiol to occur after a successful uplisting on the Nasdaq. In this regard, we are in active discussions with U.S. analysts, investment firms, and biotech investment funds to support this important initiative and I am pleased to say that the responses we are receiving from our initial meetings has been very positive and we look forward to securing a Nasdaq listing as soon as possible.


Financing

news|financial: "Your company recently received $10 million via warrants and options. How are you using the funds?"

The recent proceeds from the exercise of warrants and options have further strengthened Cardiol’s financial position. We will be utilizing these funds to support our important research and clinical development programs in heart disease, with a primary focus on our landmark Phase II/III study in high-risk CCOVID-19 patients with cardiovascular disease or risk factors for heart disease. We expect this program will also provide invaluable information concerning the cardioprotective properties of CadiolRx that may extend its therapeutic potential to a broad range of inflammatory heart disorders, including acute myocarditis and heart failure– a condition that remains a leading cause of death and disability throughout the world.


Future projects

news|financial: "You are researching the effects of CBD on various forms of heart disease in great detail and seem to have a lot going on in 2021. Even so, are there other early-stage projects that far-sighted Cardiol Therapeutics shareholders can look forward to?"

We believe we are just at the beginning of discovering the cardioprotective benefits of CBD. Beyond the focus of our current Phase II/III clinical programs that we have discussed today, we look forward to advancing the next generation of CBD-based medicines utilizing an injectable formulation to increase the efficiency by which this drug reaches sites of disease, as well as exploring its potential to reduce cardiotoxicity associated with chemotherapy.


news|financial: "Thank you very much for talking to us."

  • Biotech
  • Heart Disease
  • CBD



Conflict of interest & risk note

In accordance with §34b WpHG we would like to point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH may hold long or short positions in the aforementioned companies and that there may therefore be a conflict of interest. Apaton Finance GmbH may have a paid contractual relationship with the company, which is reported on in the context of the Apaton Finance GmbH Internet offer as well as in the social media, on partner sites or in e-mail messages. Further details can be found in our Conflict of Interest & Risk Disclosure.